CSL Ltd
AUAUDCSL Ltd (US:CMXHF) — Biotechnology. Брой борси, на които се търгуват акциите на компанията: 2. На тази страница — цена и график, дивиденти, най-големи акционери и история на броя на акциите.
За Компанията
- Уебсайт
- csl.com.au
- Връзки с Инвеститорите
- investors.csl.com/
- Сектор
- Healthcare · Biotechnology
- Централа
- Melbourne, Australia
- Изпълнителен Директор
- Gordon Naylor BEng
- Служители
- 29 000
- Основана
- 1994
- Акции в Обращение
- 479.88 млн
- Свободно Търгуеми Акции
- 478.53 млн
- Пазарна Капитализация
- 87.08 млрд AUD
- Инсайдери
- 0.02%
- Институционални Инвеститори
- 38.27%
Описание
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Най-Големи Притежатели
| Притежател | Дял | Акции | Дата на Доклада |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.49% | 7.16 млн | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.99% | 4.75 млн | 2026-06-30 |
| iShares Trust-iShares Co… | 0.75% | 3.6 млн | 2026-08-31 |
| Fidelity Concord Street… | 0.39% | 1.89 млн | 2026-07-31 |
| iShares Trust-iShares MS… | 0.36% | 1.72 млн | 2026-08-31 |
| J.P. Morgan Exch-Trd Fd.… | 0.3% | 1.45 млн | 2026-07-31 |
| Fidelity Salem Street TR… | 0.29% | 1.38 млн | 2026-07-31 |
| iShares Trust-iShares MS… | 0.28% | 1.35 млн | 2026-08-31 |
| VANGUARD Intl Eqy. INDEX… | 0.24% | 1.16 млн | 2026-07-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.22% | 1.08 млн | 2026-05-31 |
| Pacer Advisors, Inc. | 0.08% | 369 774 | 2026-06-30 |
| Naylor (Gordon) (Directo… | ≈0.01% | 40 819 | 2026-05-26 |
| McKenzie (Paul F) (Chief… | ≈0.01% | 31 053 | 2025-09-01 |
| McNamee (Brian Anthony)… | ≈0.01% | 30 561 | 2026-08-21 |
| Linton (Joy) (Chief Fina… | ≈0% | 15 096 | 2025-06-30 |
| Watkins (Alison Mary) (I… | ≈0% | 6 989 | 2026-08-21 |
| Clark (Megan Elizabeth)… | ≈0% | 5 718 | 2025-08-22 |
| Schmeltz (Andy) (Other E… | ≈0% | 5 067 | 2025-06-30 |
| Hewson (Carolyn Judith)… | ≈0% | 4 131 | 2026-08-21 |
| Price (Cameron Bruce) (I… | ≈0% | 3 559 | 2026-08-21 |
| Daniels (Brian M.D.) (No… | ≈0% | 3 400 | 2025-11-18 |
